FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $40.41M
• Dividend Yield: N/A
• Average Volume (3M): 433.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.24
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 10
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.59
• Shares Outstanding: 36,408,398
• 10 Day Avg. Volume: 222,859
• 30 Day Avg. Volume: 433,352
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -4.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $12.00
• Price Target Upside: 990.91% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

FibroBiologics, Inc. demonstrates major financial vulnerabilities due to a lack of revenue and reliance on external funding. The stock's bearish technical indicators and negative valuation metrics contribute to a low overall score. Recent funding initiatives are positive but don't fully offset the broader financial and strategic challenges.

Positive Factors

Market Opportunity

Chronic wound care represents a sizable market with $28B in healthcare spending, providing a significant opportunity for FibroBiologics.

Therapeutic Benefit

Fibroblast therapies offer a differentiated therapeutic benefit, addressing unmet needs in connective tissue formation and wound healing.

Negative Factors

Financial Performance

Fibrobiologics reported 3Q24 results with an operating loss of ($3.4M) and cash of $7.8M.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc. (FBLG) is a biotechnology company focused on the research, development, and commercialization of fibroblast-based therapeutic solutions. Operating within the healthcare sector, the company is dedicated to advancing fibroblast cell therapy applications in the treatment of various chronic diseases, including degenerative conditions and autoimmune disorders. FibroBiologics aims to leverage its proprietary technologies to develop innovative treatments that address unmet medical needs.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its proprietary fibroblast-based therapies. The company may earn money through licensing agreements, research collaborations, and partnerships with other biotechnology and pharmaceutical companies. Additionally, FibroBiologics could receive funding from grants and government programs aimed at supporting innovative healthcare solutions. The commercialization of approved therapies would also contribute to its revenue streams, potentially including direct sales, royalties, and milestone payments from partners involved in bringing the therapies to market.

FibroBiologics, Inc. Financial Statement Overview

Summary

FibroBiologics, Inc. faces significant financial challenges with no revenue generation and increasing operational losses. Reliance on external funding raises sustainability concerns, though liquidity has improved slightly.

Income Statement

FibroBiologics, Inc. has consistently reported zero revenue, indicating no sales activity or market penetration. The company shows increasing losses over the years, with negative EBIT and Net Income margins worsening. This reflects high operational costs without corresponding revenue generation, a significant concern for financial sustainability.

Balance Sheet

The company has a weak equity position, with stockholders' equity improving from negative to positive but remaining low relative to liabilities. The debt-to-equity ratio is volatile due to fluctuating equity, posing significant financial risk. However, the increase in total assets and cash reserves signals some improvement in liquidity.

Cash Flow

Operating cash flow remains negative, indicating persistent cash burn. Free cash flow is also negative, driven by operational losses. Cash inflows from financing activities have been substantial, suggesting reliance on external funding. This raises concerns about long-term cash sustainability without revenue.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-407.00K	-437.00K	-94.00K	0.00	0.00
	EBIT
-12.51M	-8.89M	-4.47M	-1.58M	-1.17M
	EBITDA
-17.21M	-15.90M	-4.37M	-1.58M	0.00
	Net Income Common Stockholders
-17.78M	-16.48M	-5.12M	-1.58M	-1.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.27M	9.16M	2.27M	407.00K	0.00
	Total Assets
4.82M	11.82M	4.82M	468.00K	0.00
	Total Debt
7.52M	1.75M	7.52M	1.52M	0.00
	Net Debt
5.26M	-7.42M	5.26M	1.12M	0.00
	Total Liabilities
8.82M	10.57M	8.82M	1.76M	0.00
	Stockholders Equity
-4.00M	1.25M	-4.00M	-1.29M	0.00
Cash Flow		Free Cash Flow
-10.52M	-6.90M	-4.07M	-1.41M	-1.17M
	Operating Cash Flow
-10.43M	-6.40M	-4.07M	-1.41M	-1.17M
	Investing Cash Flow
-87.00K	-495.00K	0.00	0.00	0.00
	Financing Cash Flow
7.58M	13.79M	5.92M	1.82M	1.17M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 1.1 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.60, and below the 200-day MA of 3.36, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 39.05 is Neutral, neither overbought nor oversold. The STOCH value of 42.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$4.27B	-16.36	-11.71%	4.83%	31.84%	-53.69%
RCUS	52 Neutral	$1.05B	―	-59.77%	―	120.51%	25.37%
BPMC	52 Neutral	$5.54B	―	-31.26%	―	104.04%	87.80%
FGEN	49 Neutral	$38.39M	―	60.38%	―	16.15%	59.81%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%
KPTI	41 Neutral	$62.62M	―	41.08%	―	-0.55%	49.85%
FBLG	37 Underperform	$40.41M	―	-267.86%	―	―	―

FibroBiologics, Inc. Corporate Events

FibroBiologics Approves Executive Bonuses for 2024

On January 23, 2025, FibroBiologics, Inc. announced that its Compensation Committee and Board of Directors approved the 2024 fiscal year annual incentive bonuses for its executive officers. The updated Summary Compensation Table reveals the total compensation, including bonuses, stock options, and other earnings for the fiscal year ended December 31, 2024. Notably, a bonus of $75,000 was approved for Robert E. Hoffman, the Interim Chief Financial Officer.

FibroBiologics Secures $5M Funding for Strategic Growth

FibroBiologics, Inc. announced the closure of the second $5 million tranche under the Standby Equity Purchase Agreement with YA II PN, LTD., part of a $25 million financing plan. This funding is expected to support general corporate purposes and demonstrates FibroBiologics’ ongoing efforts to strengthen its financial position and advance its clinical programs.

FibroBiologics Secures $25M Equity Agreement for Trials

FibroBiologics, Inc. announced a $25 million Standby Equity Purchase Agreement with YA II PN LTD., managed by Yorkville Advisors Global, LP, allowing the sale of its common stock over two years. This financing will support FibroBiologics in conducting its first-in-human trials for diabetic foot ulcers and IND-enabling studies for psoriasis, as well as further development of treatments for human longevity, multiple sclerosis, and cancer.

FibroBiologics Resolves Commitments Through Share Issuance Agreement

FibroBiologics, Inc. has entered into a Side Letter Agreement with GEM Global Yield LLC SCS and GEM Yield Bahamas Limited to issue shares and settle financial obligations. The agreement includes the issuance of 1,152,074 shares at $2.17 per share and the termination of a previous warrant agreement, effectively fulfilling outstanding commitments and leading to the termination of the share purchase agreement with GEM.